Genomic Vision reported that the company successfully completed work-package-one of a three-part research agreement for the genetic characterization of Sanofi cell banks. Two years ago, Genomic Vision began part one of partnership with Sanofi Genzyme to characterize transformed cell lines for bioproduction and to compare proprietary molecular combing technology with other laboratory methods.
Genomic Vision officials said results paved the way to a better understanding of the genetic characterization of transformed cell lines. Company scientists applied their molecular combing method, which involves a single DNA molecule analysis technology using the FiberVision® fluorescence scanner, to detect large genomic rearrangements and complex structural variations in transgene integration patterns.
This approach has the power to precisely monitor the quality of cell lines and assess their stability throughout the manufacturing process, an essential step in the development and production of numerous biological products including viral particles, recombinant therapeutic proteins, monoclonal antibodies as well as contributing to vaccine production, according to Dominique Remy-Renou, CEO of Genomic Vision.
“With resolution, visualization, and sensitivity being key requirements for genetic stability and clonality testing, molecular combing is poised to help create a new benchmark for bioproduction and cell line manufacturing,” she said, adding that the company continues to work with the National Institute of Standards and Technology (NIST) consortium to develop quality control tools to be used in genome editing-based therapies.
